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Valorization
I
n the Netherlands, approximately 150,000 people suffer from heart failure (HF). An-
nually approximately 7000 patients die due to HF and there are around 30,000 HF
hospitalizations.1 These hospital admissions and treatment of patients with severe symp-
toms are associated with high costs. In 2007 the costs for HF amounted 455 million euros, of
which 60% was due to hospitalizations.
In approximately 25% of all HF patients2, the electrical conduction pattern is disturbed
leading to a dyssynchronous electrical activation and contraction of the right and left ventricle
(LV), resulting in a reduced pump function. In 2001 a new therapy was approved by the
FDA, cardiac resynchronization therapy (CRT), which aims to resynchronize the right and
left ventricle leading to a better pump function of the heart. In the last few years, the CRT
implantation rate was >2000/year in the Netherlands alone.3 CRT has been shown to improve
cardiac pump function and quality of life, and reduce HF symptoms, hospitalization, and
mortality at the population level.4 However, benefits at the individual level vary considerably.
On the one hand, ∼20% of patients that are implanted according to current guidelines5,6 show
complete normalization of LVEF whereas a significant portion (30-50%) of patients benefit
little from this therapy.7 Such lack of response is especially undesirable since CRT requires
the implantation of a costly device during an invasive procedure. Improved patient selection
and optimal programming of the CRT device could lead to a higher response rate to CRT.
Improving patient selection
In this thesis it was shown that the baseline value of QRSarea and Tarea, both indices derived
from the vectorcardiogram (VCG), are good predictors of response to CRT. They perform
better than the established criteria QRS duration and certain LBBB criteria. Patients with
a higher baseline value of QRSarea or Tarea have a higher change of CRT response, making
both variables good measures to improve patient selection for CRT. The advantage of these
measures is that they are easily obtained and widely applicable.
As was pointed out in chapter 3 it is justified to synthesize a VCG from a 12-lead elec-
trocardiogram (ECG) using the Kors matrix. This conversion can be applied to almost any
12-lead ECG, with the only requirement being that either a common running lead or a com-
mon reference point, such as a pacing artefact, must be present. Ideally, the ECGs are stored
digitally but semi-digital ECGs as stored in a pdf-file or even paper ECGs could also be used
to calculate the QRSarea and Tarea. As we described in this thesis, the pdf-files contain vector-
graphics that embed the digital information of the displayed ECG. The digital information
can thus be extracted, making it possible to synthesize a VCG and calculate the QRSarea and
Tarea. For scanned ECGs, the program ECGscan (AMPS LLC, New York, NY, USA) can be
used to digitize the ECGs. This enables retrospective as well as prospective VCG analysis of
routinely recorded 12-lead ECGs in large patient populations.
VCG indices like QRSarea and Tarea can also be calculated in a prospective manner. Most
commercially available ECG machines already have algorithms to construct a VCG from
standard 12-lead ECGs and the beginning and ending of the QRS complex and T-wave are
often indicated. The excellent predictive power of QRSarea and Tarea for CRT response in-
dicates that these parameters deserve to be applied more frequently in clinical practice to
identify appropriate candidates for CRT.
Furthermore, if the predictive power of these VCG indices is proven in larger clinical trials,
they may be included in the official guidelines as a selection criterion for CRT implantation.
The present thesis provides important supportive data for this introduction.
Optimal programming of the CRT device
Beside optimal patient selection, optimal programming of the CRT device settings can also
play an important role in increasing the response rate to CRT. Currently, all available tools to
optimize CRT device settings are time-consuming and/or subject to noise, leading to the use
of the ‘out-of-the-box’ default settings by a vast majority of cardiologists. Furthermore, the
optimization can often only be performed during in-hospital visits, while the optimal setting
might change over time or during different levels of activity.
CRT is often employed by pacing both the right end left ventricle of the heart (biventricular
[BiV] pacing). However, several acute8 and chronic9 studies have demonstrated that in pa-
tients with sinus rhythm and intact AV conduction, LV-only pacing can be at least as effective
as BiV pacing. CRT using LV-only pacing has been shown to be most effective when the
paced LV impulse is properly timed with respect to the intrinsic activation of the right ven-
tricle (RV), ensuring appropriate fusion with intrinsically conducted activation wave fronts.
In chapter 8 of this thesis, we showed that using either the normal VCG or an electrogram
(EGM) based VCG (EGM-VCG) that can be extracted from the EGM signals measured from
the unused implanted electrodes, this exact optimal timing can easily be found. The point at
which the maximal QRS vector amplitude changes or flips direction was equal to the onset
of intrinsic activation of the RV.
A few years ago, the ADAPTIVECRTTM (trademark of Medtronic, Inc.) algorithm has
been developed that switches between BiV pacing and LV only pacing depending on con-
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duction measurements.10 When LV only pacing is applied, the ADAPTIVECRTTM algorithm
aims to perform fusion pacing which estimates the delay between atrial activation and in-
trinsic RV activation (A-RV) based on an average, general relation. With the VCG or EGM-
VCG the A-RV can be determined individually, making it more precise. It does so by obtain-
ing information during LV-only pacing at different AV-delays, while the ADAPTIVECRTTM
estimates A-RV using measurements performed when CRT is turned off. Furthermore, the
VCG and EGM-VCG methods are more robust than the ADAPTIVECRTTM algorithm since
they are independent of the exact position of the RV lead and of LV latency. Therefore, the
ADAPTIVECRTTM algorithm could be improved by using the VCG or EGM-VCG to find
the exact A-RV. The idea of using the VCG or EGM-VCG to find the exact A-RV and using
it to individualize the ADAPTIVECRTTM algorithm is already part of a patent application in
collaboration with Medtronic, Inc. To do so, there are two options. First, a single determina-
tion of A-RV, at time of implant or shortly after, could be performed using the regular ECG
from which a VCG and subsequently the maximal QRS vector amplitude can be calculated.
The exact difference in timing between A-RVsense, the delay between atrial activation and
the moment of sensing of activation on the RV lead, and A-RV can be programmed in the
device instead of the estimated difference relation used in the current ADAPTIVECRTTM al-
gorithm. This would only require adding the constant delay to the algorithm. A second option
would be to extract the A-RV from the EGM-VCG. The algorithm needed to find A-RV can
be embedded in the CRT device, making automatic and continuous optimization possible.
Again, the difference between A-RVsense and A-RV can be determined every few days, and
the ADAPTIVECRTTM algorithm can perform its usual continuous optimization with this
timing difference embedded.
The methods proposed here can be used to objectively and easily tailor the
ADAPTIVECRTTM algorithm, possibly leading to a further increase in hemodynamic
response by CRT. It does so without spending additional current, purely by optimizing
fusion pacing, which benefits form the natural activation of the RV. Because of the high
potential of the VCG or EGM-VCG to improve the ADAPTIVECRTTM algorithm, this idea
was patented together with Medtronic, Inc.
Conclusion
The findings of this thesis provide valuable tools to improve patient selection for CRT and
CRT device optimization, which have been derived from extensive basic and clinical research
prior to and during this thesis. These tools can be easily embedded in already existing sys-
tems, either ECG machines or devices. Therefore, findings from the present study may well
have significant practical implications.
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